Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00092170
Status:
COMPLETED
Last Update Posted:
2017-02-17
First Post:
2004-09-21
Brief Title:
An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections 0826-038
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Prospective Multicenter Randomized Open-Label Comparative Study to Evaluate the Safety Tolerability and Efficacy of Ertapenem Sodium MK0826 Versus TicarcillinClavulanate in the Treatment of Hospital-Acquired Pneumonia Complicated Intra-Abdominal Infections and Acute Pelvic Infections in Pediatric Patients
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute pelvic infections
Detailed Description:
The duration of treatment is 18 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004_062 | None | None | None |